The only way to recouple a decoupled share price from value is to manage through the (at times surreal) ride through the first formal agency decision outcome.
There are multiple shots on goal here and positive clinical outcomes to date, in the three target therapeutic areas, paint into your scenario very well.
The science is solid.
We need success with the process and human element aspects.
My belief and opinion is Leronlimab gets commercial traction from one of the Covid tracks. Once that occurs - expansion and scaling will quickly follow due to global demand and the complexity of managing the disease and post infection outcomes. The disease lifecycle is measured in hours and days (at least to diagnose and initiate treatment with better likelihood of success) and cascade decisions for broader deployment of the solution will accelerate the reach and use profile accordingly.
News 
Market Data 
Discover 
AI
